UBS O'Connor’s Vertex Pharmaceuticals VRTX Stock Holding History

UBS O'Connor’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,690	Closed	-$1.6M	–	1011
2022 Q2	$1.6M	Buy	+5,690	New	+$1.52M	0.02%	695

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS O'Connor's VRTX Position: Q3 2022 in Review

UBS O'Connor sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 5,690 shares — an estimated $1.6M sold.

UBS O'Connor first reported a position in VRTX in Q2 2022 and held it in 1 quarter. The position peaked at $1.6M in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

UBS O'Connor reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 5,690 Vertex Pharmaceuticals shares in Q3 2022, an estimated $1.6M.
UBS O'Connor first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 1 quarter.
UBS O'Connor's Vertex Pharmaceuticals position peaked at $1.6M in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.